Tuesday, October 25, 2011
Quebec City, Canada, October 25, 2011 – TSO3 Inc. (“TSO3” or the “Corporation”) (TSX: TOS) an innovator in low temperature sterile reprocessing solutions for medical devices in healthcare settings, announced today that the Board of Directors of the Corporation has adopted a shareholder rights plan agreement (the “Plan”) designed to foster fair treatment of all shareholders in connection with any potential take-over bid for TSO3. The Plan has been adopted as a result of the current softness in the Corporation’s share price due to general market conditions, which could lead to unsolicited offers at unfavorable conditions. While the Plan becomes effective immediately, it requires shareholder ratification within six months of its adoption. TSO3 will seek shareholder ratification of the Plan at the next annual shareholder Meeting scheduled to be held on April 25, 2012. If the Plan is not ratified as such by the shareholders, it will be void and of no further force and effect. A summary of the principal terms of the Plan will be described in the management proxy circular to be sent to all shareholders prior to the meeting.
Tuesday, October 25, 2011
Quebec City, October 25, 2011 – TSO3 Inc. (“TSO3”) (TSX: TOS) announced today that it will report Financial Results for the third quarter of 2011, for the period ending September 30 2011, on Wednesday, November 2, 2011. TSO3 will host a Conference Call and a Webcast at 10:30 A.M. (ET) the same day to discuss financial results and to update on recent activities.
Friday, September 30, 2011
TSO3 Provides an Update on Commercial Launch and Regulatory Activities – Customers Report High Satisfaction with New Sterilizer
Quebec City, Canada, September 30, 2011 – TSO3 Inc. (“TSO3”) (TSX: TOS) an innovator in low temperature sterile reprocessing solutions for medical devices in healthcare settings, today outlined commercial progress in cleared markets, as well as gave details on the program to upgrade customers of the first generation sterilizer (TSO3 125L Ozone Sterilizer) to that of the new generation sterilizer commercialized by 3M, under the brand 3M™ Optreoz™ 125-Z Sterilizer. The Company also acknowledged being actively engaged in the US regulatory process for clearance of the product in the United States.
Thursday, August 11, 2011
Quebec City, August 11, 2011 – TSO3 Inc. (“TSO3”) (TSX: TOS) an innovator in sterilization technology for medical devices in healthcare settings, announced today that Mr. R.M. (Ric) Rumble, CEO of TSO3, will be giving a corporate presentation at 11:00 a.m (ET) today, at the Canaccord Genuity Annual Growth Conference.
Tuesday, August 9, 2011
Quebec City, August 9, 2011 – TSO3 Inc. (“TSO3”) (TSX: TOS) an innovator in sterilization technology for medical devices in healthcare settings, posted its highest quarterly revenues in its second quarter of 2011. For the period ending June 30, 2011, the Company posted revenues of $703,000 from the sales of 3M™ Optreoz™ 125-Z Sterilizers, accessories, consumables and service contracts, as well as license revenues. This amount also includes sales of supplies and service contracts on first generation sterilizers (125L). These revenues compare to Q2 2010 revenues of $545,604, for the sale of 3M™ Optreoz™ Sterilizers, accessories, supplies and service contracts to 3M™ for training purposes. For the six-month period ended June 30, 2011, revenues amounted to $892,554 compared to $733,878 for the same period in 2010. The difference is explained by higher sales of private labelled 3M™ Optreoz Sterilizers and Accessories as a result of initial 3M™ commercial activity.
Sorry, no posts matched your criteria.